Clinical Trial Update: A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of LAS41004 formulation in mild-to-moderate psoriasis using an intra-individual comparison.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• LAS41004

Snippet

Sponsor: Almirall, S.A. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED